JO2273B1 - Dihydro-benzo derivatives [B] [1.4] di-azin-2-one - Google Patents

Dihydro-benzo derivatives [B] [1.4] di-azin-2-one

Info

Publication number
JO2273B1
JO2273B1 JO200233A JOP20020033A JO2273B1 JO 2273 B1 JO2273 B1 JO 2273B1 JO 200233 A JO200233 A JO 200233A JO P20020033 A JOP20020033 A JO P20020033A JO 2273 B1 JO2273 B1 JO 2273B1
Authority
JO
Jordan
Prior art keywords
benzo
dihydro
derivatives
diazapin
mglur2 antagonists
Prior art date
Application number
JO200233A
Other languages
Arabic (ar)
English (en)
Inventor
ميوتل فينست
ويتشمان جيورغن
ادم جيو
جيوتستشي اروين
جوهانز ولترينغ ثوماس
Original Assignee
اف . هوفمان لاروش ايه جي
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by اف . هوفمان لاروش ايه جي filed Critical اف . هوفمان لاروش ايه جي
Application granted granted Critical
Publication of JO2273B1 publication Critical patent/JO2273B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JO200233A 2001-04-12 2002-04-10 Dihydro-benzo derivatives [B] [1.4] di-azin-2-one JO2273B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01109126 2001-04-12

Publications (1)

Publication Number Publication Date
JO2273B1 true JO2273B1 (en) 2005-04-07

Family

ID=8177127

Family Applications (1)

Application Number Title Priority Date Filing Date
JO200233A JO2273B1 (en) 2001-04-12 2002-04-10 Dihydro-benzo derivatives [B] [1.4] di-azin-2-one

Country Status (37)

Country Link
US (1) US6548495B2 (enExample)
EP (1) EP1379522B1 (enExample)
JP (1) JP4043953B2 (enExample)
KR (1) KR100566178B1 (enExample)
CN (1) CN1268626C (enExample)
AR (1) AR035456A1 (enExample)
AT (1) ATE287883T1 (enExample)
AU (1) AU2002310912B2 (enExample)
BG (1) BG108253A (enExample)
BR (1) BR0208887A (enExample)
CA (1) CA2441771C (enExample)
CZ (1) CZ20033002A3 (enExample)
DE (1) DE60202761T2 (enExample)
DK (1) DK1379522T3 (enExample)
EC (1) ECSP034796A (enExample)
ES (1) ES2235044T3 (enExample)
GT (1) GT200200072A (enExample)
HR (1) HRP20030791B1 (enExample)
HU (1) HUP0400991A3 (enExample)
IL (2) IL158021A0 (enExample)
JO (1) JO2273B1 (enExample)
MA (1) MA27011A1 (enExample)
MX (1) MXPA03009317A (enExample)
MY (1) MY130369A (enExample)
NO (1) NO325300B1 (enExample)
NZ (1) NZ528345A (enExample)
PA (1) PA8543201A1 (enExample)
PE (1) PE20021072A1 (enExample)
PL (1) PL367086A1 (enExample)
PT (1) PT1379522E (enExample)
RU (1) RU2270197C2 (enExample)
SI (1) SI1379522T1 (enExample)
SK (1) SK13692003A3 (enExample)
UY (1) UY27259A1 (enExample)
WO (1) WO2002083665A1 (enExample)
YU (1) YU79103A (enExample)
ZA (1) ZA200307242B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL357433A1 (en) 1999-10-15 2004-07-26 F.Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
WO2005014002A1 (en) * 2003-07-25 2005-02-17 F. Hoffmann-La Roche Ag Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
CN101056857B (zh) 2004-11-05 2010-12-01 弗·哈夫曼-拉罗切有限公司 异烟酸衍生物的制备方法
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
ES2369866T3 (es) 2007-04-19 2011-12-07 F. Hoffmann-La Roche Ag Derivados de dihidro-benzo[b][1,4]diazepin-2-ona-sulfonamida.
UA100126C2 (en) 2007-09-14 2012-11-26 Аддекс Фарма С.А. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4'] bipyridinyl-2'-ones
JP5433579B2 (ja) * 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 1,3−二置換−4−フェニル−1h−ピリジン−2−オン
ATE516272T1 (de) 2007-09-14 2011-07-15 Ortho Mcneil Janssen Pharm 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としての3−アザビシクロ[3.1.0]ヘキシル誘導体
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
DK2430022T3 (da) 2009-05-12 2013-12-02 Janssen Pharmaceuticals Inc 1,2,4-Triazolo[4,3-a]pyridinderivater og deres anvendelse til behandlingen eller forebyggelse af neurologiske og psykiatriske lidelser
KR20120035158A (ko) 2009-05-12 2012-04-13 얀센 파마슈티칼즈, 인코포레이티드 1,2,4?트리아졸로[4,3?a]피리딘 유도체 및 mGluR2 수용체의 양성 알로스테릭 조절자로서의 그의 용도
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2012062759A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JP5852665B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
PT2649069E (pt) 2010-11-08 2015-11-20 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
EP2925292A1 (en) 2012-10-23 2015-10-07 F. Hoffmann-La Roche AG Mglu2/3 antagonists for the treatment of autistic disorders
ES2685025T3 (es) 2013-02-28 2018-10-05 Eisai R&D Management Co., Ltd. Derivado de tetrahidroimidazo[1,5-d][1,4]oxazepina
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
UA121965C2 (uk) 2014-01-21 2020-08-25 Янссен Фармацевтика Нв Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування
MY182627A (en) 2014-01-21 2021-01-27 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
EP3134089A2 (en) 2014-04-23 2017-03-01 F. Hoffmann-La Roche AG Mglu2/3 antagonists for the treatment of intellectual disabilities
EP3154954B1 (en) * 2014-06-10 2022-02-09 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU953819A1 (ru) * 1980-08-25 1991-09-23 Физико-химический институт АН УССР 1-(Гидразинокарбонил)алкил-1,2-дигидро-3Н-1,4-бенздиазепин-2-оны, обладающие транквилизирующими и противосудорожными свойствами
EP1210338A2 (en) * 1999-08-05 2002-06-05 IGT Pharma Inc. 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
WO2001029011A2 (en) * 1999-10-15 2001-04-26 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
PL357433A1 (en) * 1999-10-15 2004-07-26 F.Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists

Also Published As

Publication number Publication date
YU79103A (sh) 2006-05-25
RU2270197C2 (ru) 2006-02-20
AR035456A1 (es) 2004-05-26
NO20034496D0 (no) 2003-10-08
JP4043953B2 (ja) 2008-02-06
HRP20030791A2 (en) 2005-06-30
SI1379522T1 (en) 2005-04-30
EP1379522A1 (en) 2004-01-14
US6548495B2 (en) 2003-04-15
RU2003130648A (ru) 2005-04-10
MA27011A1 (fr) 2004-12-20
DE60202761T2 (de) 2006-01-12
NO20034496L (no) 2003-10-08
US20020198197A1 (en) 2002-12-26
EP1379522B1 (en) 2005-01-26
PA8543201A1 (es) 2002-10-31
MY130369A (en) 2007-06-29
PT1379522E (pt) 2005-05-31
AU2002310912B2 (en) 2005-06-16
DK1379522T3 (da) 2005-05-30
HRP20030791B1 (en) 2006-06-30
KR20030088502A (ko) 2003-11-19
BG108253A (bg) 2005-03-31
HUP0400991A2 (hu) 2004-08-30
BR0208887A (pt) 2004-06-29
CN1522252A (zh) 2004-08-18
IL158021A (en) 2010-04-15
NZ528345A (en) 2005-04-29
DE60202761D1 (de) 2005-03-03
KR100566178B1 (ko) 2006-03-29
MXPA03009317A (es) 2004-02-12
CA2441771A1 (en) 2002-10-24
ES2235044T3 (es) 2005-07-01
HUP0400991A3 (en) 2009-06-29
WO2002083665A1 (en) 2002-10-24
ECSP034796A (es) 2003-12-01
HK1068339A1 (en) 2005-04-29
CA2441771C (en) 2008-12-30
UY27259A1 (es) 2002-10-31
GT200200072A (es) 2003-06-19
JP2004525965A (ja) 2004-08-26
CZ20033002A3 (cs) 2004-03-17
PE20021072A1 (es) 2002-12-07
IL158021A0 (en) 2004-03-28
ATE287883T1 (de) 2005-02-15
PL367086A1 (en) 2005-02-21
SK13692003A3 (sk) 2004-05-04
ZA200307242B (en) 2004-12-16
CN1268626C (zh) 2006-08-09
NO325300B1 (no) 2008-03-25

Similar Documents

Publication Publication Date Title
MY140271A (en) Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists ii
JO2273B1 (en) Dihydro-benzo derivatives [B] [1.4] di-azin-2-one
MY176608A (en) Dihydrobenzodiazepin-2-one derivatives iii
TWI265928B (en) A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw
MY140693A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
MXPA03000428A (es) Derivados de tetrahidro-heterociclo-acepinil-pirimidina.
YU11501A (sh) Derivati 4,4,-biarilpiperidina sa aktivnošću na receptor opijata
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
TW200500344A (en) Novel compounds
MY121047A (en) Bicyclo [2.2.1] heptanes and related compounds
GEP20104959B (en) Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
UA72881C2 (uk) Похідні тієнопіридину, фармацевтична композиція з використанням таких сполук (варіанти), проміжна сполука
WO2002036562A3 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
AU2002307049A1 (en) Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
WO2002051832A3 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
BG105731A (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
PT1463735E (pt) Imidazo-2,1-b-1,3,4-tiadiazol sulfonamidas
BG104983A (en) Aryl fused azapolycyclic compounds
MXPA04001419A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson.
TW200510331A (en) Heteroaryl-substituted imidazole derivatives
PT1651592E (pt) Novas dibenzo[b,f]oxepino-10-carboxamidas e suas utilizações farmacêuticas
MXPA06000193A (es) Derivados de imidazol iii.
CA2299036A1 (en) 4-phenyl-4-heteroarylpiperidine derivatives
JO2495B1 (en) Derivatives of dihydropenzene-2-one III